NCT03691844CompletedPhase 2
A Placebo-controlled, Double-blind, Randomized, Trial of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms
Amzell7 sites in 3 countries444 target enrollmentStarted: October 4, 2018Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 444
- Locations
- 7
- Primary Endpoint
- WOMAC Pain Sub-score
Study Overview
Brief Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week trial of a formulation of AMZ001 once or twice daily versus placebo twice daily, including a single-blind treatment group with a commercial gel four times daily.
Detailed Description
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week trial of a formulation of AMZ001 once or twice daily versus placebo twice daily, including a single-blind treatment group with a commercial gel four times daily. Participants will be evaluated for osteoarthritis by X-ray images of the knees and one knee will be selected for treatment as the target knee. The study gel will be applied directly to that knee throughout the 4 weeks of the study.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Masking Description
3 treatment arms will be double-blind, the 4th (comparator) will be single-blind
Eligibility Criteria
- Ages
- 40 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Osteoarthritis of the knee, according the American College of Rheumatology (ACR) clinical and X-ray criteria.
- •Pain score rated on an 11-point numerical rating scale of the target knee of ≥ 20 and ≤ 45 out of 50 in response to the WOMAC pain sub-score (5 questions), at the time of screening, after washout of any pain relief medication.
- •Women of child-bearing potential must use at least an acceptably effective method of contraception from enrollment up to at least 3 months after the study end.
- •Knee pain in the target knee for 14 days of the preceding month (knee pain due to osteoarthritis and not due to another condition such as bursitis, tendinitis, etc.) based on subject report.
- •On stable pain therapy (i.e., at least 3 days per week for the previous month) with an oral or topical NSAID prescribed by physician for 30 days prior to the Screening Visit and/or prescribed over-the-counter.
- •Except for osteoarthritis, in reasonably good health as determined by the Investigator.
Exclusion Criteria
- •Known or suspected hypersensitivity to diclofenac, other non-steroidal anti-inflammatory drugs or related substances including aspirin, any of the components in either of the investigation products, or any physical impediment to gel application on the target knee.
- •Injection of corticosteroids or hyaluronic acid in the target knee within 6 months of screening or into any other joint within 30 days of screening.
- •High dose oral/injected corticosteroid treatment of more than 14 days during the past 6 months prior to screening.
- •Major surgery or arthroscopy of the target knee within the previous year prior to screening.
- •Planned surgery of the target knee within the next 3 months.
- •Presence of an additional non-osteoarthritic disease affecting either knee, such as rheumatoid arthritis, psoriasis, gout or pseudo-gout, if there is reason to believe that the disease(s) may significantly interfere with the interpretation of the clinical response to the study drug.
- •Medical history of coronary artery bypass graft surgery.
- •Current cancer or treatment for cancer within the past five years, with the exception of non-melanoma skin cancer, unless affecting the target knee area.
- •Secondary osteoarthritis of the target knee, previous procedures or trauma affecting joint of the target knee.
- •Reported incidence of any of the following diseases: known osteoarthritis of the hip(s) if pain in hip(s) exceeds that of the target knee using the WOMAC Hip Pain subscore, presence of significant back pain, or at least one migraine attack within the past 12 months before screening, as reported by the subject.
- •Body Mass Index > 45.0 kg/m
- •Generalized skin irritation, previous skin reactions upon use of topical NSAIDs, current skin irritation or redness at the planned site of gel application, or significant skin disease including psoriasis, as judged by the investigator.
- •Known presence of a ulcer or any gastrointestinal bleeding within 6 months prior to screening.
- •Use of moderate or higher doses of opioid medication for the treatment of pain within 6 weeks before the screening visit.
- •Use of duloxetine, pregabalin, or gabapentin within 4 weeks before the screening visit.
- •History of alcohol or drug abuse within the past year prior to randomization.
Arms & Interventions
AMZ001 + Placebo
Experimental
on the target knee
Intervention: AMZ001 (Drug)
AMZ001
Experimental
on the target knee
Intervention: AMZ001 (Drug)
Placebo
Placebo Comparator
on the target knee
Intervention: Placebo (Drug)
Comparator
Active Comparator
Diclofenac gel on the target knee
Intervention: Comparator (Drug)
Outcomes
Primary Outcomes
WOMAC Pain Sub-score
Time Frame: baseline, week 4
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-score (questions 1-5; score 0 \[no pain\]-50 \[extreme pain\]) on target knee. The WOMAC scores were normalized to a 0-100 point scale for data analysis, where higher scores indicate greater pain, stiffness or difficulty in performing daily tasks.
Secondary Outcomes
- WOMAC Total Score and WOMAC Function and Stiffness(baseline, week 4)
- WOMAC Pain Sub-score (Dose Comparison)(baseline, week 4)
- Impact of Osteoarthritis on Daily Living (PGA Score)(baseline, week 4)
- ICOAP Scores(baseline, week 4)
- Physical Function(baseline, week 4)
- WOMAC Total Score and WOMAC Function and Stiffness (Dose Comparison)(baseline, week 4)
- Proportion of Responders as Per OMERACT-OARSI Criteria(week 4)
- WOMAC Pain Weight-bearing Score and Non-weight-bearing Score (Dose Comparison)(baseline, week 4)
- Physical Function (Dose Comparison)(baseline, week 4)
- Work Productivity(baseline, week 4)
- Total Dose of Rescue Medication(weeks 1 through 4)
- Time Between Baseline and First Use of Rescue Medication(weeks 1 through 4)
- ICOAP Scores (Dose Comparison)(baseline, week 4)
- WOMAC Pain Weight-bearing Score and Non-weight-bearing Score(baseline, week 4)
- Change in Quality of Life: EQ5D VAS Score(baseline, week 4)
Investigators
Study Sites (7)
Loading locations...
Similar Trials
Completed
Phase 2
A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint DiseaseRheumatoid ArthritisNCT04004429SynAct Pharma Aps105
Not yet recruiting
Phase 4
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment PatientsVascular Cognitive ImpairmentNCT05050604Chong Kun Dang Pharmaceutical418
Not yet recruiting
Phase 4
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive ImpairmentMild Cognitive ImpairmentNCT05041790Chong Kun Dang Pharmaceutical418
Completed
Phase 3
Comparative Study of BAY86-5300 With an Extended Flexible Regimen for EndometriosisEndometriosisNCT01697111Bayer312
Completed
Phase 2
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic DermatitisAtopic DermatitisPruritusNCT04018027Cara Therapeutics, Inc.401